Ribon, backed by biopharma majors, raises $65M to take PARP7 inhibitor deeper into the clinic

Ribon, backed by biopharma majors, raises $65M to take PARP7 inhibitor deeper into the clinic

Source: 
Fierce Biotech
snippet: 

Ribon Therapeutics has raised $65 million to advance a  pipeline led by a PARP7 inhibitor deeper into the clinic. The financing positions Ribon to build on work to target stress support pathways in cancer and inflammation.